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Abstract 
 
Background 
Enhanced Recovery After Surgery (ERAS) is a multimodal approach to 
perioperative care that combines a range of interventions in order to enable early 
mobilization and feeding after surgery. We investigated the feasibility, clinical 
effectiveness and cost savings of an ERAS program at a major US teaching hospital. 
 
Methods 
Data were collected from consecutive patients undergoing open or laparoscopic 
colorectal surgery during two time periods, before and after implementation of an 
ERAS protocol. Data collected included patient demographics, operative, and 
perioperative surgical and anesthesia data, need for analgesics, complications, 
inpatient medical costs, and 30-day readmission rates. 
 
Results 
There were 99 patients in the traditional care group, and 142 in the ERAS group. 
The median length of stay (LOS) was 5 days in the ERAS group compared with 7 
days in the traditional group (p < 0.001).  The reduction in LOS was significant for 
both open procedures (median 6 days vs. 7 days, p = 0.01), and laparoscopic 
procedures (4 days vs. 6 days, p < 0.0001). ERAS patients had fewer urinary tract 
infections (13% vs. 24%, p = 0.03). Re-admission rates were lower in ERAS patients 
(9.8% vs. 20.2%, p=0.02). 
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Discussion 
Implementation of an Enhanced Recovery protocol for colorectal surgery at a 
tertiary medical center was associated with a significantly reduced LOS and 
incidence of urinary tract infection. This is consistent with other studies in the 
literature and suggests that Enhanced Recovery programs could be implemented 
successfully and should be considered in US hospitals. 
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Introduction 
 
Evidence-based medicine has been arguably the biggest driver for the change in 
practice and improvement in outcomes seen over the last twenty years, yet much 
routine perioperative care in colorectal surgery is not evidence-based.  Despite lack 
of evidence for preoperative bowel preparation in colorectal surgery, routine use of 
nasogastric tubes, and nil by mouth instructions until bowel sounds are heard 
postoperatively, all three are still widely practiced.1-3 
 
With traditional perioperative care, factors such as pain, stress, immobilization and 
postoperative ileus can lead to a length of stay (LOS) of greater than 10 days and 
complication rates of 45–48% after major elective open colorectal surgery.4,5 If a 
complication occurs this has been shown to be a primary determinant of long-term 
survival.6 Khuri et al analyzed data from over 100,000 patients undergoing major 
surgery and demonstrated that the occurrence of any one of the 22 types of 
complications collected in the National Surgical Quality Improvement Program 
(NSQIP) database reduced median patient survival over the following 10 years by 
69%.6 Caring for patients with complications is also expensive, with the average 
cost of a surgical complication estimated at $10,000.7  
 
Enhanced Recovery After Surgery (ERAS) is a multidisciplinary perioperative care 
pathway that aims to standardize perioperative care, and apply evidence-based 
medicine to all aspects of a patient’s operative journey.8  ERAS pathways also aim 
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to reduce the stress response to surgery; and have been shown to reduce 
complications, and LOS after major surgery, with the added benefit of reducing 
healthcare costs.2,9,10 
 
Although Enhanced Recovery has been described for some time11, implementation 
is not widespread. There are many barriers to implementation that need to be 
overcome to achieve success. As a result, within the United States few major 
centers have reported adoption of an ERAS program. However, as we move toward 
a new era in the delivery of healthcare, a program that can improve quality yet 
reduce healthcare costs is of significant interest.  The purpose of this study was to 
assess the clinical effectiveness and cost savings of an ERAS protocol for colorectal 
surgery at a tertiary medical center. We hypothesized that adoption of an ERAS 
protocol reduces length of hospital stay, complications, and medical costs when 
compared with traditional care. 
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Methods 
 
 
After approval from Duke University Medical Center IRB (ref. no. Pro00028555, 
approved 2/16/2011), we compared data from consecutive patients undergoing 
open or laparoscopic colorectal surgery within the ERAS protocol with a previous 
cohort of patients before introduction of the ERAS protocol. Three colorectal 
surgeons at Duke University Medical Center performed all of the procedures.  
 
Study design 
We conducted a quantitative observational comparative effectiveness study.  
The study consisted of three phases. 
1. Retrospective analysis of perioperative data from patients undergoing 
surgery according to traditional practices from January to June 2009. After 
this time practice changes gradually occurred in anticipation of 
implementation of the full ERAS protocol in 2010. 
2. Implementation phase: the ERAS protocol was implemented in March 2010 
after training of staff members. A three-month implementation period 
allowed all staff to become familiar with the protocol. 
3. Post-implementation phase: between June and December 2010, 
perioperative data where collected prospectively from patients undergoing 
surgery within the ERAS protocol. 
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Data collected included patient demographics, operative, and perioperative 
surgical and anesthesia data, need for analgesics, complications, inpatient medical 
costs, and 30-day readmission rates. All patients who underwent an elective colon 
or rectal resection by one of the three colorectal surgeons within the pre- and post-
implementation periods were included in this analysis. There were significant 
differences in patient management before and after introduction of the ERAS 
protocol.  
 
Pre-Intervention Management 
Before introduction of the ERAS pathway, there was little standardization of care. 
Patients were fasted from midnight on the day of surgery, and all patients received 
bowel preparation. All other patient management was at the discretion of the 
surgical and anesthesia providers. Placement of thoracic epidurals was rare due to 
surgical preference for enoxaparin to be given 2 hours preoperatively (see 
RESULTS). Intraoperative fluid administration was based on changes in 
hemodynamics (BP and HR) and urine output. Early mobilization and feeding were 
not undertaken 
 
Post-implementation Management: ERAS protocol 
After implementation of the ERAS pathway, care was standardized using a pathway 
that was adapted from the evidence described in the ERAS consensus statement 
(Supplementary Tables 1 and 2).2 Patients in the ERAS group were educated in the 
preoperative surgical clinic about the ERAS pathway and were encouraged to ask 
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questions. Routine bowel preparation was not performed for colonic procedures, 
and patients were allowed to drink clear fluids until 3 hours preoperatively. 
Patients also were given 240 mL of an oral preoperative drink (GatoradeTM, 
PepsiCo, Purchase, NY), which they were told to drink 3 hours preoperatively. 
 
In all patients without contraindications an epidural catheter was placed at the T8-
T10 level, while in the preoperative holding area. Small doses of midazolam and 
fentanyl were given to facilitate epidural insertion and maintain patient comfort. 
After placement of the epidural and before skin incision patients received 
thromboprophylaxis with heparin 5000 i.u. subcutaneously, and perioperative 
antibiotics were administered before surgical incision.  
 
All patients received general anesthesia with an oral endotracheal tube. 
Intraoperative analgesia was provided using a single epidural dose of 
hydromorphone at induction (0.4-0.8 mg based on body weight) followed by an 
infusion of bupivacaine (2.5 mg/mL at 3-6 mL/h). No intraoperative intravenous 
opioids were given after induction of anesthesia without discussion with the 
attending anesthesiologist. 
 
Intravenous (IV) crystalloid (Lactated Ringers) 1 L was given during induction of 
anesthesia. An infusion of Lactated Ringers was then started and maintained 
throughout the procedure using a dedicated infusion pump (set at 3 mL/kg/h for 
laparoscopic colectomy, and 5 mL/kg/h for open colectomy, based on lean body 
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weight). All patients received intraoperative Goal-Directed Fluid Therapy (GDFT) 
with a minimally invasive cardiac output monitor. Boluses of IV colloid were given 
to optimize stroke volume (SV) using a 10% algorithm (see Supplementary Table 
2).  The monitor used was normally the Esophageal Doppler (EDM™ Deltex Medical, 
Inc., Irving, TX ). The LiDCORapid™ (LiDCO Ltd., Cambridge, UK) was used as an 
alternative when invasive blood pressure monitoring was performed. The need for 
an arterial line was based on the clinical judgment of the anesthesiologist.  
Orogastric tubes, placed following the induction of anesthesia, were removed at the 
end of the procedure. Surgical drains were not routinely used. 
 
Postoperatively patient’s urinary catheter was removed on the day after surgery. 
Postoperative analgesia was provided using an epidural local anesthetic/opioid 
infusion (bupivacaine 0.125% and hydromorphone 10 mcg/mL) for up to 72 hours. 
Regular adjunctive analgesia with acetaminophen and NSAIDS was used whenever 
possible, and patients were transitioned to oral opioids after removal of the 
epidural catheter. Patients were encouraged to drink liquids immediately after 
surgery. IV fluid administration was discontinued once adequate oral intake was 
achieved, usually on the first morning after surgery. All preoperative medications 
were recommenced when patients tolerated oral intake. 
 
Patients were cared for in an environment that encouraged early mobilization. 
They were encouraged to be out of bed on the day of surgery, and for at least six 
hours on every subsequent day. 
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Cost Analysis  
 
Patient bills for the index hospitalization period were obtained from the Duke 
University Medical Center (DUMC) patient data repository. Medical costs were 
estimated by multiplying hospital department charges on study subject bills by 
their associated ratios of cost to charge from DUMC’s Medicare Cost Reports. For 
reporting purposes, Medicare Cost Report departments were aggregated into 
clinically meaningful units. Results are presented as unadjusted mean values by 
treatment strategy with estimated differences and 95% confidence intervals before 
and after adjusting for age, sex, and procedure type. Unadjusted and adjusted non-
parametric bootstrap analyses were used to estimate the variability of cost 
estimates and to develop a cost acceptability curve that showed the percent of 
bootstrap samples for which use of the ERAS protocol would be cost saving versus 
the traditional protocol.12,13 
 
 
Statistical Analysis 
A sample size analysis showed that a Mann-Whitney rank-sum test based on a 
symmetric distribution with expected mean difference of 2 days in LOS and a 
standard deviation of 5 would have 80% power with 106 patients per group.  If the 
group distributions of LOS are skewed, 100 patients per group provides 95% 
power assuming a 65% probability of a shorter LOS in the ERAS group.  All relevant 
patient characteristics, operative and postoperative data were summarized with 
descriptive statistics and compared between the pre- and post- implementation 
groups with t-tests, rank-sum tests, or chi-squared tests as appropriate. The 
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primary clinical outcome was postoperative hospital LOS. LOS was defined as 
postoperative number of nights in the hospital. Secondary outcomes were days to 
first stool, estimated blood loss, postoperative pain scores (measured twice a day), 
postoperative IV morphine equivalents14, surgical site infection (SSI, includes 
superficial incisional infection, deep incisional infection, organ space infection and 
wound disruption), urinary tract infusion (UTI), readmission rate, and death. Pain 
was assessed using a 0-10 verbal response scale (VRS), where “0” represents no 
pain and “10” represents worst possible pain twice a day as part of the standard of 
care nursing protocol. The highest pain reported each day was recorded from the 
day of surgery until discharge or the fifth day post-op. Then the set of maximum 
pain scores were averaged for each patient to give each patient an average 
maximum pain score.  Pain scores were compared between therapy groups using a 
rank-sum test. SSI and UTI were diagnosed according to criteria from the American 
College Of Surgeons National Surgical Quality Improvement Program.15  
 
Because of its skewed distribution, LOS was initially compared between groups 
with an unadjusted rank-sum test.  For covariable-adjusted testing, a parametric 
multivariable regression tested the effect of ERAS on a log-transformation of LOS, 
adjusting for surgical approach (laparoscopic or open) and patient characteristics 
including ASA class, age, gender, BMI, surgical duration, and pelvic procedure.  The 
interactions of effects of ERAS and all these co-variables were also tested. Because 
a laparoscopic approach has a significant effect on LOS, and was also more frequent 
after ERAS implementation, special attention was given to distinguishing between 
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these two effects.  The interaction was tested in the multivariable model, and as a 
follow-up the ERAS effect was tested in open and laparoscopic groups separately, 
both with unadjusted rank sum tests and with multivariable regression. The log 
transformation of LOS did not attain Kolmogorov-Smirnoff test standards for 
normality, but it greatly reduced the test statistics as well as skewness and 
kurtosis. These indicators, along with the consistency between the rank-sum test 
and a t-test with the log-transformed values, gave us confidence that the 
distribution was not unduly influencing the results of the parametric adjusted 
regression. All secondary clinical outcomes were compared with t-tests, rank-sum 
tests, or chi-square tests without co-variable adjustment.  All comparisons were 
made at a significance level of 0.05, and all analyses were performed with SAS® 
version 9.3 (SAS Institute, Cary, NC). 
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Results 
There were 99 patients in the traditional care group, and 142 in the ERAS group. 
The relevant patient characteristics and surgical details are included in Table 1. 
There was no significant difference in age, sex, BMI, or ASA status between the two 
groups. Operations did not differ statistically in terms of length of surgery (median 
300 min in the traditional group and 270 min in the ERAS group, p=0.11), however 
significantly more patients in the ERAS group underwent a laparoscopic rather 
than an open surgical approach (56.3% vs. 40.4%, p = 0.01). 
 
The median LOS was 5 days (interquartile range (IQR) = 3-7) in the ERAS group 
compared with 7 days (IQR = 5-8) in the traditional group.  The p-values for the 
effect of ERAS on LOS were p < 0.0001 in both the unadjusted rank-sum test and in 
the adjusted covariate model.  The reduction in median LOS was significant for 
open procedures (6 days vs. 7 days, p = 0.01), and laparoscopic procedures (4 days 
vs. 6 days, p < 0.0001, rank-sum tests) (Table 2).  While surgical approach had a 
significant effect on LOS (p <0.0001 in both the unadjusted rank-sum test and in 
the adjusted covariate model), the effect of ERAS was statistically consistent 
regardless of approach. That is, in the model adjusting for approach and other 
covariables, the interaction between ERAS and approach was non-significant 
(p=0.5398, Table 2b). In addition to surgical approach, the other significant co-
variables in our model were female gender (shorter stay, p=0.0016) and shorter 
duration of surgery (shorter stay, p=0.0032). There was also a significant reduction 
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in re-admission rates within 30 days in ERAS patients compared to patients in the 
traditional group (9.8% vs. 20.2%, unadjusted chi-square p = 0.02). 
 
Thoracic epidural analgesia (TEA) was used in 92% of patients in the ERAS group 
compared to 18% of patients in the traditional group (p<0.0001).  This resulted in a 
significant reduction in the intraoperative and postoperative morphine 
requirements in the ERAS patients compared to the traditional group (Table 3). 
Pain scores were significantly lower in the ERAS group compared to controls 
(Table 3). 
 
GDFT was used in all patients in the ERAS group. ERAS patients received less 
crystalloid (mean 2261 mL vs. 3170 mL, p<0.0001) and more colloid (mean 
1072mL vs. 716 mL, p<0.0001) than patients in the traditional group, resulting in 
an overall reduction in the amount of intraoperative IV fluid administered in ERAS 
patients. There was no significant difference in intraoperative urine output 
between the two groups. 
 
In the ERAS group, 74% (105/142) of patients began clear fluids on the day of 
surgery, compared to 15% (15/99) in the traditional group (p <0.0001). Early 
mobilization was accomplished in 70% (99/142) of patients in the ERAS group 
ambulating on postoperative day (POD) 1. There was a significant reduction in the 
duration of ileus in the ERAS patients compared with traditional care (mean time to 
first stool 2.4 days vs. 3.4 days, p = 0.0001). 
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There was a significant reduction in urinary tract infection in ERAS patients (13% 
vs. 24%, p = 0.03), presumably related to the earlier removal of Foley catheters. 
There was a lower percentage of surgical site infection (28% vs. 37% p = 0.15) in 
ERAS patients that did not reach statistical significance.  
 
Patients undergoing laparoscopic surgery in the traditional group received more 
opioids and experienced more pain (Table 4). Intraoperative and postoperative 
opioid use, the average postoperative pain score, and the highest postoperative 
pain score, were all significantly reduced in the ERAS group. 
 
Overall there was no statistically significant difference in unadjusted total medical 
costs for patients in the ERAS pathway and traditional care groups ($18,377 vs. 
$20,537; difference, -$2161; 95% CI, -$6352 to $2030; p=0.31) (Table 5A). Similar 
results for the ERAS pathway versus traditional care were observed after 
adjustment for age, sex, and procedure type (difference, -$1854; 95% CI, -$6072 to 
$2363; p=0.39) (Table 5B). While the use of open surgery was more costly than 
laparoscopic surgery, this difference also was not significant after adjustment 
(difference, $2849; 95% CI, -$1315 to $7012; p=0.18). Use of the ERAS protocol 
was associated with reductions in room-related costs and an increase in medical 
and surgical supply costs before and after adjustment.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
The net reduction in medical costs achieved with the ERAS protocol was 
approximately 10% of traditional care medical costs before and after adjustment. 
These results were confirmed in bootstrap analyses in which use of the ERAS 
pathway versus traditional care would be expected to achieve some degree of cost 
saving in 85% of unadjusted and 82% of adjusted medical cost samples (Figures 1 
and 2).   
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Discussion 
 
Implementation of an Enhanced Recovery protocol for colorectal surgery at a 
tertiary medical center was associated with a significantly reduced LOS, incidence 
of urinary tract infection, and readmission rates. The reduction in LOS was similar 
to other studies in the literature from diverse centers around the world in open 
colorectal surgery.4,5,16 
 
For patients without complications, LOS is largely determined by the duration of 
postoperative ileus.  Once the ileus has resolved most patients are discharged home 
within 1-2 days.  Several perioperative factors including preoperative fasting and 
bowel preparation, analgesic and anesthetic techniques, and perioperative fluid 
management influence the duration of ileus.17 Enhanced recovery programs aim to 
minimize ileus to facilitate immediate feeding and mobilization on the day of 
surgery.  
 
Our study showed a greater reduction in LOS for laparoscopic surgery than for 
open surgery. This was surprising and could possibly be due to the fact that there 
was a greater change in practice from baseline in the laparoscopic procedures. Only 
7.5% of patients undergoing laparoscopic surgery in the traditional group received 
epidural anesthesia compared to 92.5% in the ERAS group.  This resulted in a large 
reduction in opioid use and pain scores in patients undergoing laparoscopic 
colectomy within the ERAS program. 
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Compared with traditional care the re-admission rate was also reduced in patients 
following the ERAS protocol, demonstrating that patients were physiologically 
ready to leave hospital earlier with the ERAS pathway. 
 
The ERAS pathway can be divided into three components – preoperative, 
intraoperative, and postoperative. The key principals of the preoperative 
component are to prepare the patient (and the relatives) psychologically for the 
care program, managing expectation and to prevent a prolonged fasting state.  This 
is achieved through a combination of nutritional supplements, the avoidance of 
routine bowel preparation, allowing clear fluids until 2 hours before induction of 
anesthesia, and use of a preoperative carbohydrate drink.  These interventions are 
evidence-based, and improve subjective well-being, primarily by reducing thirst.18 
 
Intraoperative elements are the key to successful ERAS pathways, and lay the 
groundwork to enable early mobilization and feeding. Minimally invasive surgery is 
an important component. 8,19 The two major anesthetic factors are fluid 
management optimization and the minimization of intravenous opioids, which can 
delay the return of normal bowel function.20  
 
The first goal of intraoperative fluid management should be avoidance of fluid 
excess, which has shown to be associated with adverse outcomes.21,22 The amount 
of intraoperative crystalloid given in our study was significantly reduced compared 
to similar surgeries ten years ago when it was not unusual to receive greater than 6 
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liters of intraoperative crystalloid.23,24  Only 20% of an intravenous crystalloid 
bolus remains in the circulation after 1 hour,25 with the rest distributed in the 
extravascular space and contributing to perioperative weight gain, bowel wall 
edema, and prolonged ileus.21  In a recent analysis of the different elements of an 
ERAS protocol, avoidance of fluid excess was the single most important factor.26 
In addition, GDFT with a minimally invasive cardiac output monitor can optimize 
stroke volume.  Multiple studies have shown that GDFT reduces hospital LOS and 
complications after major surgery.27  These two goals of fluid therapy are not 
mutually exclusive and can be achieved with a background crystalloid infusion 
supplemented by colloid boluses to maximize stroke volume. However, there is 
currently a lack of information on the role of GDFT within an ERAS program. 
 
Thoracic epidural anesthesia is well established as the analgesic technique of 
choice in open major abdominal surgery, with studies showing consistently 
superior analgesia to intravenous opioids in the first 72 hours after surgery.28  TEA 
is also highly effective at reducing postoperative ileus compared to intravenous 
opioids, with a reduction in the duration of ileus after open colectomy of 
approximately 36 hours.20  
 
The choice of analgesic technique for laparoscopic surgery is more controversial, 
and many centers use alternative multimodal regimes incorporating transversus 
abdominis plane (TAP) blocks29 or spinal anesthesia.30 We chose to administer 
epidural anesthesia for all patients in our ERAS program, including those 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 23 
undergoing laparoscopic surgery, because our institution is a tertiary referral 
center where a significant proportion of the laparoscopic procedures are complex 
operations involving rectal resection, pouch formation, inflammatory bowel 
disease patients, or redo operations. In our patient population, patients undergoing 
laparoscopic surgery seemed to benefit from epidural analgesia with a dramatic 
reduction in pain scores and postoperative opioid use that was as significant for 
laparoscopic surgery as open procedures. 
 
Other centers have shown that epidurals can impair discharge after laparoscopic 
colectomy by reducing mobility and complicating fluid management.30 Why is this 
so different to our results? Different patient populations may play a role and 
certainly laparoscopic surgeries cannot all be considered equal. Very few of our 
patients had simple colectomies without rectal work or stoma formation, where 
discharge can often be achieved within 2-3 days, and therefore epidural analgesia 
may not be beneficial. Further studies are needed to evaluate different regional 
techniques in different types of laparoscopic colorectal surgery. 
 
Successful implementation of the preoperative and intraoperative elements of an 
ERAS pathway enables mobilization and feeding to occur on the day of surgery.  
Patients are encouraged to sit out of bed for at least 6 hours on every postoperative 
day; and with only evidence-based use of surgical drains, catheters, or nasogastric 
tubes.31 .   
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The percentage of patients having a surgical site infection (SSI) in our study was 
high. SSIs are the most common complication after colorectal surgery, and although 
some centers have reported SSI rates less than 10%,32 the incidence of SSIs after 
colorectal surgery has been reported to be as great as 25-30% in several large, 
observational studies.33-35 Our SSI rate decreased after introduction of the ERAS 
program but remains high and we are currently evaluating a bundle of care 
measures to reduce bacterial contamination of the surgical site. Future strategies 
should also concentrate on timely recognition and management of complications 
when they occur, which is an important determinant of postoperative 
mortality.36,37 
 
There was a trend towards lower medical costs in the ERAS group that did not 
reach statistical significance. However, cost data typically are skewed and require a 
larger sample than was available in the present study to detect significant 
differences. Therefore bootstrap analysis was used to look at the distribution of the 
difference in mean values of the two samples, and showed that the ERAS protocol 
would be expected to cost less than control in 85% of unadjusted and 82% of 
adjusted medical cost samples. This was mainly related to the reduction in LOS in 
the ERAS group. 
 
The main limitation of our study is that it was not a blinded randomized controlled 
trial (RCT).  Furthermore, all of the elements of the ERAS protocol were introduced 
simultaneously. Thus, it is impossible to determine which elements may be 
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responsible for the observed outcome differences. Unfortunately, it is practically 
impossible to blind a bundle of care with so many different interventions. 
Additionally the complexity in implementing ERAS programs would make a 
randomized controlled trial (RCT) to assess their clinical effectiveness technically 
challenging. Implementation programs can take several months and involves 
education and training for all perioperative care providers.  It is therefore difficult 
and may indeed be confusing and potentially unsafe for patients to be randomized 
to traditional or ERAS care as would occur in a RCT. However, in our study there 
were no significant differences in the baseline characteristics between the patients 
during the control and the intervention periods, and the magnitude of the change in 
LOS was substantial. 
 
Another limitation is that non-clinical confounders, such as the availability of the 
surgical team to make discharge decisions can affect the time of discharge from 
hospital. Whilst no practice changes occurred in discharge planning during the 
study the change in organizational workflows after the introduction of the ERAS 
pathway may have improved the discharge process in the ERAS group compared to 
the traditional group. 
 
It is possible that the observed benefits could be due to a laparoscopic approach 
and the use of epidural analgesia. It is also possible that it is not the epidural per se 
that causes the observed benefits but the early feeding and mobilization that the 
epidural facilitated. In other words, if the patient undergoing traditional care has a 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 26 
good working epidural but is still fasted and undergoing bed rest, the benefits of 
the epidural in aiding recovery may not be realized. 
 
Finally, it is also possible that all elements of the protocol are important with the 
reduction in LOS and complications proportional to the number of elements 
implemented.26 As the enhanced recovery process develops, further research will 
aim to identify crucial elements of the protocol.  Some interventions may turn out 
to be more important than others, and some may be nonessential. However, 
current evidence suggests that adherence to the ERAS protocol as a whole is the 
best approach.26 
 
In conclusion, we showed a significant reduction in LOS after implementation of an 
enhanced recovery program for colorectal surgery. The reduction in LOS was 
significant for patients undergoing open and laparoscopic colorectal resection. Our 
data support the evidence that enhanced recovery programs should be considered 
as the new standard of care for patients undergoing elective colorectal resection. 
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Table 1. Patient demographics, anthropometrics, and clinical characteristics 
 
 
 
Traditional 
N=99 
ERAS 
N=142 
P-Value 
Age (year) 56 ± 15 58 ± 15 0.54 
Male/female 43/56 69/73 0.43 
Height (cm) 171 ± 10 172 ± 10 0.41 
Weight (Kg) 81 ± 20 83 ± 20 0.47 
BMI 27.7 ± 5 28.5 ± 7 0.78 
ASA Physical Status  
I 
II 
III 
IV 
3 
39 
53 
4 
0 
53 
87 
2 
0.0715  
 
Type of surgery 
Colon 
Pelvic 
54 (55%) 
45 (45%) 
75 (53%) 
67 (47%) 
0.79 
Laparoscopic approach 
(%) 
40.4 % 56.3 % 0.01 
Duration of surgery 
(min)* 
300 ± 136 270 ± 126 0.11 
 
Data are expressed as mean ± SD or n (%) 
* Incision to end of surgery 
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Table 2a. Length of stay 
 
 
 Mean ± SD Median (IQR) 
  
 Traditional ERAS Traditional ERAS 
Diff   
(95% CI)* 
P-
Value** 
All procedures 
(days) 
8.3 ± 8.1 6 ± 4.2 7 (5, 8) 5 (3, 7) 2 (1 - 2) <0.0001 
Open procedures 
(days) 
9.3 ± 6.6 7.1 ± 3.9 7 (6, 9) 6 (5, 8) 1 (0 - 2) 0.0133 
Laparoscopic 
procedures (days) 
6.9 ± 5 5.2 ± 4.2 6 (4.5, 7.5) 4 (3, 5.5) 2 (1 - 2) <0.0001 
 
*  Difference between medians, and estimated 95% Confidence limits for the difference. 
** P-values in this table are from unadjusted rank-sum tests comparing therapy groups. 
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Table 2b. Multivariable linear regression on log-transformed LOS  
 
Factor 
Beta 
Coefficient 
P-Value 
Laparoscopic 
approach 
-0.218 0.0001 
ERAS protocol -0.253 <0.0001 
ASA 3-4 0.128 0.0516 
Duration of 
surgery 
(minutes) 
0.0007 0.0033 
Female gender -0.200 0.0019 
Interaction: 
Laparoscopic 
surgery and 
ERAS protocol 
-0.080 0.5398 
 
Duration of surgery is the number of minutes from incision to end of surgery.  No 
transformation of this number was necessary, as none provided meaningful improvement in 
the correlation with log(LOS) 
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Table 3: Patient Outcomes 
 
 
 
Traditional ERAS P-Value 
POD to first oral liquid 1.8 ± 1.9 0.5 ± 1 <0.0001 
POD to first stool 3.4 ± 1.7 2.4 ± 1.6 0.0001 
OR crystalloid 3170 ± 1621 2261 ± 1282 <0.0001 
OR colloid 716 ± 519 1072 ± 530 <0.0001 
OR blood 83 ± 321 80 ± 474 0.142 
OR FFP 20 ± 128 33 ± 209 0.9408 
OR estimated blood loss 319 ± 314 246 ± 430 0.0003 
OR urine output 460 ± 349 490 ± 318 0.2799 
Highest postoperative pain 
score 
6.8 ± 2.3 5.6 ± 2.7 0.0004 
Average pain score 
Days 0-5 
4.9 ± 2.1 3.3 ± 1.9 <0.0001 
Total intraoperative 
morphine equivalents (mg) 
53.1 ± 28 20.8 ± 23.5 <0.0001 
Total postoperative 
morphine equivalents (mg) 
Median (IQR) 
Mean 
 
 
120 (69 – 267) 
196 ± 191 
 
 
29.8 (10 – 85) 
85 ±175 
 
<0.0001 
Surgical Site Infection (%) 37.3% 28.8% 0.16 
Urinary Tract Infection (%) 24.2% 13.4% 0.03 
Readmission (%) 20.2% 9.8% 0.02 
Death (%) 1% 0% 0.41 
 
POD = Postoperative day; OR=Operating room 
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Table 4: Pain scores and opioid consumption by surgical approach 
 
 
 
Median (IQR) Mean ± SD 
 
Traditional ERAS Traditional ERAS P-Value 
Highest 
postoperative 
pain score 
Open 7 (5, 9) 6.5 (5, 8) 6.6 ± 1.7 6.3 ± 2.3 0.36 
Lap 7.5 (6, 8) 5 (3, 7) 7.1 ± 1.8 5 ± 2.9 <0.0001 
Average pain 
score Days 0-5 
Open 4.5 (3.4, 6.5) 
3.5 (2.2, 
4.8) 
4.9 ± 2.3 3.7 ± 1.9 0.0020 
Lap 4.6 (3.9, 6) 3 (1.3, 4.6) 4.8 ± 1.7 3.1 ± 1.9 <0.0001 
Total 
intraoperative 
morphine 
equivalents 
(mg) 
Open 
56.7 (33.4, 
70.1) 
15 (10, 
25) 
56.9± 32.3 
25.8 ± 
33.1 
<0.0001 
Lap 
43.2 (35.1, 
60.2) 
15 (10, 
20) 
47.5 ± 19.1 
16.9 ± 
10.4 
<0.0001 
Total 
postoperative 
morphine 
equivalents 
(mg) 
Open 
171 (63.4, 
351) 
40 (16.5, 
134) 
220 ± 196 
123 ± 
242 
<0.0001 
Lap 
110.1 (71.8, 
162) 
20 (6.7, 
61.7) 
159 ± 179 
53.7 ± 
74.5 
<0.0001 
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Table 5A:  Medical Costs (US $) 
 
 
Hospital 
Department 
Groups 
Medical costs 
 
Unadjusted 
Difference 
(ERAS - 
traditional) 
Lower 
CI 
(95%) 
Upper 
CI 
(95%) 
Unadjusted 
P-Value Traditional 
(n=99) 
ERAS 
(n=142) 
Non-ICU 3121 2551 -570 -1074 -66 0.027 
ICU 3251 2019 -1232 -2979 516 0.17 
Pharmacy 1350 853 -497 -946 -47 0.03 
Medical and 
Surgical 
Supplies 
6380 7186 806 -283 1896 0.15 
Lab & ECG 1343 1018 -325 -671 21 0.07 
Radiology 411 404 -7 -282 269 0.96 
OR + PACU 3403 3383 -19 -260 222 0.88 
Anesthesia 248 234 -14 -32 5 0.14 
Blood related 251 139 -112 -270 47 0.17 
Dialysis 0 0 0    
Other 776 579 -197 -743 350 0.48 
Total 20,537 18,377 -2161 -6352 2030 0.31 
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Table 5B:  Adjusted Medical Costs ($, US) 
 
 Hospital 
Department 
Groups 
Adjusted 
Difference 
(ERAS - 
traditional) 
Lower 
CI 
(95%) 
Upper 
CI 
(95%) 
Adjuste
d P-
Value 
Non-ICU -509 -1013 -6 0.047 
ICU -1072 -2834 691 0.23 
Pharmacy -463 -914 -12 0.044 
Medical and 
Surgical 
Supplies 
684 -410 1778 0.22 
Lab & ECG -265 -612 82 0.13 
Radiology 16 -263 295 0.91 
OR + PACU 20 -220 261 0.87 
Anesthesia -12 -30 7 0.21 
Blood related -89 -249 71 0.27 
Dialysis -167 -722 387 0.55 
Other     
Total -1854 -6072 2363 0.39 
 
*Estimated differences and 95% confidence intervals were adjusted for age, sex, and procedure type.   
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Legend 
 
Figure 1: Unadjusted cost savings 
Cumulative distribution chart depicting the percent of bootstrap sample 
iterations in which the ERAS treatment strategy would be expected to be cost 
saving versus control using unadjusted values.  
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Supplementary Table 1.  
Duke University Colorectal Surgery ERAS Protocol Summary 
 
PHASE OF CARE, 
LOCATION 
INTERVENTION 
SURGICAL PLANNING, 
SURGICAL CLINIC 
 
Identify elective surgery patients who can benefit from participation 
Educate patients about the track and our expectations 
Reinforce with a written copy of our plan and expectations 
Screen for malnutrition, tobacco abuse, and diabetes (H&P, labs) 
PREOPERATIVE 
ASSESSMENT, 
PREOPERATIVE 
ASSESSMENT CLINIC 
 
Routine preoperative screening, specific attention to known risk 
factors 
Distribute 
 Nutritional supplements if serum albumin <3.5 
 Smoking cessation info 
 Chlorhexidine sponges for 2 preoperative showers 
 Carbohydrate drink for morning of surgery (GatoradeTM) 
Reinforce with written instructions 
DAY OF OPERATION, 
PREOPERATIVE 
HOLDING AREA 
 
Identify ERAS patients and initiate protocol 
Epidural anesthesia placement – T8-12 region 
Thromboprophylaxis with heparin 5000U sc after placement of 
epidural 
 
INTRAOPERATIVE, 
OPERATING ROOM 
 
 
Antibiotic prophylaxis before incision 
Sequential compression devices placed before induction of anesthesia 
Use epidural throughout case without any intravenous opioids 
Goal-directed intravenous fluid therapy 
Orogastric tube removed before leaving OR 
Foley discontinued in OR, except for pelvic operations 
POSTOPERATIVE CARE, 
SURGICAL WARD 
 
Diet begins night of surgery 
Ambulation begins night of surgery 
Head of bed at 30 degrees at all times 
Continue epidural for up to 72 hours postoperatively 
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Supplementary Table 2.  
 
Anesthesia colorectal enhanced recovery guidelines 
 
 
INTVENTION PROTOCOL 
THORACIC EPIDURAL 
 
 
T 8-12 region 
5000U subcutaneous heparin can be given after placement 
Hydromorphone 0.4mg-0.6mg before induction of anesthesia 
Lidocaine 2% bolus at least 10 minutes pre-incision (40-100mg) 
Run infusion of 0.25% bupivacaine throughout case (3-6 ml/hr.) 
No intraoperative iv opioids after induction without discussion with 
the Attending Anesthesiologist 
Switch to bupivacaine 0.125%/hydromorphone 10mcg/ml in epidural 
pump before leaving for PACU at end of case. 
 Settings: Infusion 4-6 ml/hour; 2ml bolus every 30 minutes 
 
GOAL-DIRECTED FLUID 
THERAPY 
 
 
1000 ml LR bolus – commenced in preoperative holding area to be 
infused during induction and then finished. 
LR infusion for rest of case based on LEAN BODY WEIGHT (max 80Kg)  
 5ml/Kg/hr. for open cases (max 400ml/hr.) 
 3ml/Kg/hr. for laparoscopic cases (max 240ml/hr.) 
Esophageal Doppler placed after induction. 
Record initial Stroke Volume (SV). 
After incision (after pneumoperitoneum for laparoscopic cases) give a 
250ml colloid bolus over <15 min (suggest five 50ml syringe pushes). 
 If SV increases by >10 % repeat bolus. 
 If SV increases by < 10% patient does not require a further 
bolus. 
 Record peak value achieved. 
 If still hypotensive consider phenylephrine infusion. 
 Give a further colloid bolus when SV drops 10% from peak 
value. 
 Repeat cycle. 
Max VoluvenTM dose 50 ml/Kg 
Reduce LR to 2ml/Kg/hr. before transfer to PACU. 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Manuscript (All Manuscript Text Pages in MS Word format, including Title Page, References and Figure Legends)
Click here to download high resolution image
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
